RxDoctor Payments Data

Nancy Eisele, MD

Ophthalmology · Wichester, VANPI 1952318370

Payments from drug & device makers

$3,540in general payments, 2019–2025

Across 104 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$1K
  • Alcon$601
  • NEW World Medical,inc.$488
  • AbbVie$355
  • Novartis$158
  • Aerie Pharmaceuticals, Inc.$133
  • plus $655 from 20 others

What the payments were for

  • Travel & lodging$93126%
  • Food & beverage$2,59773%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,540 in reported general payments places this provider in the 75th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$505,799
Medicare patients
1,206
Services billed
3,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost149$68,350
RestasisCyclosporine44$48,985
CombiganBrimonidine Tartrate/Timolol52$21,797
Cyclosporine34$12,226
Alphagan PBrimonidine Tartrate15$5,255
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$3,768
Travoprost16$3,194
Latanoprost303$3,112
Prednisolone Acetate64$2,481
Brimonidine Tartrate23$2,272
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$695
Atropine Sulfate13$496
Dorzolamide Hcl21$483
Tropicamide16$174
Timolol Maleate11$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$355$144,388260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Wichester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →